Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit the concept of synthetic lethality and offer great promise in the treatment of tumors with deficiencies in homologous recombination (HR) repair. PARPi exert antitumor activity by blocking Poly(ADP-ribosyl)ation (PARylation) and...
Main Authors: | Yu-Yi Chu, Clinton Yam, Hirohito Yamaguchi, Mien-Chie Hung |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Journal of Biomedical Science |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12929-022-00870-7 |
Similar Items
-
Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
by: Maria Giulia Nizi, et al.
Published: (2023-08-01) -
Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
by: Sayra Dilmac, et al.
Published: (2023-07-01) -
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
by: Michela Palleschi, et al.
Published: (2021-07-01) -
Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
by: Rosario Prados-Carvajal, et al.
Published: (2021-12-01) -
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01)